BofA Lowers Price Target for Madrigal Pharmaceuticals

BofA has lowered its price target for Madrigal Pharmaceuticals, Inc. (MDGL) from $550 to $542. The company stated that Rezdiffra's launch in MASH has been impressive, but debate has shifted to whether that momentum can continue. The analyst reduced the firm's 2028 Rezdiffra revenue forecast from $2.7 billion to $2.6 billion after discussions with key opinion leaders and prior management feedback.

Madrigal Pharmaceuticals and Ribo Partnership

Ribo and Madrigal Pharmaceuticals, Inc. (MDGL) achieved the first candidate drug nomination milestone under their siRNA collaboration for MASH on July 1. Ribo stated that the partnership consists of multiple preclinical assets targeting liver diseases.

■Ribo's co-CEO and Global R&D President, Li Ming Gan, said the companies reached the milestone within months.

■The partnership combined Madrigal's clinical expertise in MASH with Ribo's siRNA discovery and delivery capabilities.

■Both partners plan to accelerate the development of the novel therapy.

Investment Interest

Madrigal Pharmaceuticals, Inc. (MDGL) is a biopharmaceutical company. It delivers novel therapeutics for metabolic dysfunction-associated steatohepatitis in the United States. While we acknowledge the potential of MDGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Markets are closely watching the price target change for Madrigal Pharmaceuticals and the company's developments in MASH. This change brings discussions about whether the momentum of Rezdiffra's launch can continue. The company's siRNA collaboration and developments in MASH continue to attract investors' attention.